Zura Bio's dual BAFF/IL-17A antibody heads toward Phase 2 HS readout
TibuSHIELD will test whether hitting BAFF and IL-17A together beats placebo on lesion count in hidradenitis suppurativa, a field where single-target IL-17A drugs have already failed.
Executive Summary
- Zura Bio's Phase 2 hidradenitis suppurativa trial is approaching a placebo-controlled readout that will test its dual BAFF and IL-17A mechanism against a disease where single-pathway IL-17A drugs have already produced mixed results.
- The trial's enrollment and timeline moved through several registry updates but settled at a stable target, and the design itself, randomized and double-blind, is built to produce a decision-grade comparison against placebo.
- Hidradenitis suppurativa already has an active field of IL-17A-targeted antibodies in later-stage testing, so the readout's value rests on whether the added BAFF-blocking component shows a benefit those single-target drugs have not fully delivered.
- A lesion-count reduction that clears placebo by a margin distinguishing it from the existing IL-17A class would extend the case for dual-pathway antibody targeting in inflammatory skin disease beyond this one trial.
The trial
TibuSHIELD (NCT06993610) is a global, randomized, double-blind, placebo-controlled Phase 2 study evaluating tibulizumab in adults with moderate to severe hidradenitis suppurativa. Participants are randomized across two tibulizumab dose arms and placebo, with a 16-week primary efficacy period followed by a 12-week safety follow-up and an optional open-label extension. The primary endpoint is percent change from baseline in total abscess and inflammatory nodule count at Week 16, and secondary endpoints include the proportion of patients achieving HiSCR50 and HiSCR75, along with DLQI, patient global assessment, and skin pain measures. "Hidradenitis suppurativa remains a difficult condition to manage, with many patients experiencing persistent disease activity despite currently available treatments," said Alexa B. Kimball, MD, MPH, professor of dermatology at Harvard Medical School, when the trial launched. NCT06993610+1Tibulizumab Skin Healing and Inflammation Evaluation for Lasting DefenseNCT06993610Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis SuppurativaMay 20, 2025
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Mechanism and stake
Tibulizumab is designed to neutralize both BAFF, a B-cell survival factor, and IL-17A, a cytokine already targeted by approved therapies in inflammatory skin disease. "Tibulizumab's dual mechanism of action, targeting both BAFF and IL-17A, offers a novel approach for the potential treatment of hidradenitis suppurativa," said Kiran Nistala, MBBS, PhD, Zura Bio's chief medical officer, at the trial's launch. Peer trials confirm the asset is not first-in-class: Novartis's secukinumab, MoonLake Immunotherapeutics's sonelokimab, and UCB Pharma's bimekizumab all target IL-17A in hidradenitis suppurativa or closely related inflammatory skin indications. What tibulizumab has not yet demonstrated is whether adding the BAFF arm produces a benefit beyond what IL-17A blockade alone delivers, since no completed trial has tested this combination in this indication. Zura+1Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis SuppurativaMay 20, 2025Tibulizumab Skin Healing and Inflammation Evaluation for Lasting DefenseNCT06993610
Registry moves
The trial's enrollment target moved from 180 to 225 patients, briefly reverted to 180, then returned to 225 by February 2026. The primary completion date shifted from September 1, 2026 to November 1, 2026 over the same period. Sponsor guidance through 2025 consistently pointed to a Q3 2026 topline readout, while a more recent corporate update referenced Q4 2026 for the same milestone. The final enrollment target represents no net change from where it started, which the operational model treats as a routine, not elevated, variance pattern. NCT06993610+1Tibulizumab Skin Healing and Inflammation Evaluation for Lasting DefenseNCT06993610Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis SuppurativaMay 20, 2025
The competitive bar
IL-17A-targeted antibodies in hidradenitis suppurativa carry a recorded Phase 2 failure rate of 25%, with one termination among four completed or terminated trials sharing the target. Eight active industry trials are currently studying IL-17A in this indication, indicating a field with sustained interest but no drug in this class yet reaching a validated durable outcome here. Against that backdrop, the informative result for TibuSHIELD would be a Week 16 lesion-count reduction, and a HiSCR50/75 response rate, that separates from what single-target IL-17A antibodies have shown in the same population, since that is the comparison the dual-pathway rationale is built to answer. NCT06993610Tibulizumab Skin Healing and Inflammation Evaluation for Lasting DefenseNCT06993610
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.